Matthew Yan

Stock Analyst at CLSA

(3.86)
# 1,918
Out of 4,994 analysts
45
Total ratings
58.5%
Success rate
14%
Average return

Stocks Rated by Matthew Yan

RemeGen Co., Ltd.
Aug 25, 2026
Reiterated: Buy
Price Target: $136.90$144.80
Current: $79.80
Upside: +81.45%
Innovent Biologics, Inc.
Dec 8, 2025
Reiterated: Buy
Price Target: $120.10
Current: $103.30
Upside: +16.26%
BeOne Medicines AG
Nov 7, 2025
Reiterated: Buy
Price Target: $264.40$288.00
Current: $216.60
Upside: +32.96%
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Oct 19, 2025
Reiterated: Buy
Price Target: $548.60
Current: $488.40
Upside: +12.33%
Duality Biotherapeutics, Inc.
May 22, 2025
Initiated Coverage: Buy
Price Target: $268.30
Current: $213.60
Upside: n/a
BeOne Medicines AG
Nov 13, 2024
Reiterated: Buy
Price Target: $270$263
Current: $365.67
Upside: n/a
Daiichi Sankyo Company, Limited
Oct 31, 2024
Reiterated: Buy
Price Target: ¥6,800¥7,000
Current: ¥2,954
Upside: n/a
HUTCHMED (China) Limited
Aug 3, 2023
Reiterated: Buy
Price Target: $40.96
Current: $22.16
Upside: n/a